WATS3D® Greatly Enhances Detection of Barrett's Esophagus and Dysplasia

CDx Diagnostics, Inc., a pioneer in medical diagnostics, has announced a ground-breaking study demonstrating the effectiveness of their WATS3D AI Platform in detecting Barrett's esophagus (BE) and dysplasia. The results, published in The American Journal of Gastroenterology, underscore the platform's ability to significantly improve early cancer detection during GERD screenings.

The study, titled Adjunctive Use of WATS-3D In Symptomatic GERD Patients Increases Detection of Barrett's Esophagus and Dysplasia, was led by Dr. Nicholas J Shaheen and involved 23,933 patients. The findings revealed that incorporating WATS3D into GERD screenings identified 20% more cases of Barrett's esophagus and doubled the number of dysplasia diagnoses compared to traditional biopsy methods. This innovative tool had a profound impact on patient care, influencing the clinical management of over 90% of cases based on findings which would have been missed by forceps biopsy alone. Alarmingly, one in five patients would have remained unaware of their precancerous condition without the aid of WATS3D.

Dr. Shaheen, Chief of the Division of Gastroenterology & Hepatology at the University of North Carolina School of Medicine, remarked on the study's significance: "Compared to forceps biopsy alone, WATS3D identified around 20% more Barrett's cases that would've been missed. We also observed nearly double the dysplasia diagnoses." This study marks the largest clinical evaluation of WATS3D to date and showcases its substantial impact on early detection and patient outcomes.

Duane Dorn, Chief Operating Officer of CDx Diagnostics, expressed the company's commitment to enhancing early detection rates: "The landmark findings highlight how our AI imaging technology can effectively transform early detection rates and empower physicians to intervene before progression to esophageal cancer. Improving patient lives through earlier detection is the driving force behind our innovations."

CDx's WATS3D technology is specifically designed to address the limitations of traditional forceps biopsies, which frequently fail to confirm intestinal metaplasia in patients with GERD. By leveraging artificial intelligence and 3D imaging, WATS3D reliably identifies precancerous cells, providing crucial insights for the management of Barrett's esophagus. The study showed that WATS3D detected intestinal metaplasia in 19.3% of patients and identified dysplasia in 45% of cases that were missed by forceps biopsy, demonstrating a 77% adjunctive and 18% absolute yield in intestinal metaplasia detection among patients with endoscopic BE criteria.

CDx Diagnostics' mission is to empower physicians with advanced technology to prevent esophageal cancer, one patient at a time. Their proprietary diagnostic platform integrates computer imaging, artificial intelligence, molecular biology, and 3D cytopathology to detect precancerous changes earlier and with greater accuracy than conventional methods. These tests are designed to seamlessly integrate into physician workflows, requiring minimal time while offering cost-effective and widely reimbursed results. By addressing a critical gap in current diagnostic practices, CDx's innovations have enabled the early detection of numerous cancers and precancerous conditions, paving the way for timely and effective treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!